RxDoctor Payments Data

Alicia Roston, MD

Urology · Wailuku, HINPI 1700380029

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (55.4%), travel and lodging and education — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Axonics, Inc. at 42.7% of the total. Reporting peaked in 2024 at $2,702 and has fallen 72.2% since, to $750 in 2025.

$4,147in general payments, 2019–2025

Across 81 payments — averaging $51.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$2K
  • Astellas Pharma US Inc$503
  • Pfizer$337
  • Johnson & Johnson$320
  • Boston Scientific$256
  • AbbVie$161
  • plus $798 from 11 others

What the payments were for

  • Travel & lodging$1,49536%
  • Food & beverage$2,29755%
  • Education$3559%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,147 in reported general payments places this provider in the 70th percentile of 46 urology providers in Hawaii.

See all urology providers in Hawaii

Medicare billing

Part B allowed, 2024
$168,359
Medicare patients
374
Services billed
2,051

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron108$114,287
GemtesaVibegron13$18,577
Estradiol91$6,015
Tamsulosin Hcl233$3,401
Solifenacin Succinate72$2,747
Finasteride147$2,261
Tolterodine Tartrate12$1,529
Testosterone11$1,426
Desmopressin Acetate13$1,227
Cephalexin36$672
Ciprofloxacin Hcl82$306
Alfuzosin Hcl ErAlfuzosin Hcl12$283
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim55$266
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst18$239
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen56$236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$503$114,287108 claims
Sumitomo Pharma America, Inc.Gemtesa$125$18,57713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 46 urology providers in Hawaii.

Other urology in Wailuku

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →